Targazyme’s current focus:

Allogeneic stem cell transplantation (Allo-SCT) is a potential cure for advanced leukemia, lymphoma and other life-threatening blood diseases, unfortunately about half of the transplanted patients die within a year. Opportunistic infections and Graft versus Host Disease (GvHD) account for about 40% of these deaths.

Targazyme’s lead clinical product, TZ101, is aimed at reducing infections and GvHD by improving the engraftment, growth and/or immuno-modulatory functions of key immune cells present in the various stem grafts (cord blood, bone marrow and peripheral blood).

Immuno-oncology, and more specifically, cell-based immuno-oncology treatments are emerging as a new class of anti-cancer therapies. Our technology is applicable to various cell types associated with anti-cancer activities such as T-cells and Natural Killer cells.